Ok Pharmacy Review

What Ok Pharmacy charges

• Sermorelin: $99/mo — the reduced price; the same listing prints a struck-through higher figure, and the body text says monthly fixed pricing and describes the supply as approximately one month with one injection weekly
• Glutathione: $149 — the reduced price for a related listing under the same resold brand, printed beside a higher struck-through figure with no period stated anywhere

A reseller listing, and what that changes

This page is a retail listing for a product branded by a different company, complete with a struck-through price, a reduced price and an outbound button to the brand's own site.

It is therefore a second published price for a brand whose own site publishes none, at a different unit.

The two must not be merged: one is a pharmacy's retail listing, the other is a clinic's visit fee, and they answer different questions.

Each is recorded against the page it was read on, with the host named, which is the only way a reader can tell which is which.

Third-party testing, at second hand

The specification block says the brand states that its partner pharmacies run quality-control checks in registered laboratories.

That is a pharmacy reporting a brand's description of a third pharmacy's practice, three parties deep, with no document at any level.

Every attribute on the page was swept for a certificate — not just the link targets — and nothing was found.

This is recorded as claimed and unreachable, because writing it as third-party testing would credit a document that does not exist.

Money, and the unit it is measured in

Its listing prints a reduced figure beside a struck-through one for a resold branded peptide, and states a monthly supply in the body text; a second listing under the same brand carries a reduced figure with no period stated at all.

On documentation the finding is more specific: ⛔ claimed at second hand and unreachable — the page says the brand states that its partner pharmacies perform routine quality-control checks in registered laboratories, and links no certificate anywhere.

One hundred and thirty-seven of the two hundred and ten sellers here publish a figure somewhere on their own site, and this is one of them.

The host itself was checked in the same pass as everything above: 404 at a nonsense path, same effective path, which is what any absence recorded here rests on.

Where this row sits against the rest

One hundred and seventy-six of the two hundred and ten sellers here publish no state list at all, and this is one of them, so eligibility is settled inside an intake rather than before one.

Sixteen of the two hundred and ten sellers here name the facility that fills an order; this is one of the one hundred and ninety-four that do not, so there is no facility a reader can look up.

Four of the two hundred and ten sellers here describe lab work as included in what they charge, and this is not one of them.

It declares two of the sixteen compounds this site tracks, and one hundred and one sellers here declare more, so it is one of the narrower menus here.

How we verified this

• Read every page cited on this row as rendered text in a browser-equivalent fetch, with the response decompressed before any character was counted.
• Fired a nonsense-path control at this host in the same run and compared the address requested with the address actually served, so no claim here rests on a status code alone.
• Joined every text node before scanning for a dollar sign, so a figure split across nested elements could not read as an absence.
• Swept every attribute on the product page for a certificate rather than only the link targets, and found none behind the testing sentence.
• Recorded the operating company named for the resold brand as this pharmacy's assertion, attributed to this page, rather than moving it onto the brand's own row.
• Kept the struck-through figure and the reduced figure both in the qualifier without asserting the higher one was ever charged.
• Recorded the second listing's figure as carrying no period, because the page states none for it.
• Screened this seller in the live federal warning-letter record by entity and by brand, with a known-good positive control and a nonsense negative control fired in the same run.
• Read the company column of every returned record rather than accepting a full-text match, and attached no letter on a name match.
• Swept every attribute on the pages read for a certificate, not only the link targets, because certificates in this market hide in data attributes and lightbox images.
• Re-counted the state-list, pharmacy-naming and lab-inclusion claims against the current roster rather than reusing figures from an earlier pass.